Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia

 Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia

Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia

Shots:

  • Kite enters into a two-year research collaboration and license agreement with HiFiBiO to discover novel targets and Abs against AML
  • HiFiBiO will receive an up front and will utilize its technology platform to identify novel AML targets and anti-AML specific Abs to support Kite’s development of cell therapies
  • Kite to get an exclusive option to opt-in any targets emerges during the collaboration, for which HiFiBiO will receive an additional payment and is eligible to receive development, regulatory and commercial milestones along with royalties on sales of Abs

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Technology Networks

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post